Board Members in Alphabetical Order:

• Christian Bogdan, Mikrobiologisches Institut, Universitätsklinikum Erlangen, DE
• Meinrad Busslinger, Institute of Molecular Pathology (IMP) Vienna, AT
• Tony Green, Cambridge Institute for Medical Research, University of Cambridge, UK
• Klaus Pfeffer, Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine-Universität Düsseldorf, DE
• Valeria Poli, Molecular Biotechnology Center and Dept. Of Genetics, Biology and Biochemistry, University of Turin, I
• (Florian Greten (II. Medizinische Klinik und Poliklinik (Gastroenterologie), Technische Universität München, DE) was not able to attend the SAB meeting.

Celebrating the 20th year of Jak-STAT research, highlighting recent basic developments in the field, relevance to diseases and new therapeutics; National Institutes of Health, Bethesda, MD; September 22-24, 2011

The Vienna based Jak-Stat consortium contributed to the meeting with 3 talks and 1 poster entitled:

• 'Stat5: Oncogen and Tumor Suppressor' - Richard Moriggl, Ludwig Boltzmann Institute for Cancer Research Vienna


• 'Chromatin-associated Phosphorylation of Stat Transactivation Domains Is Catalyzed by Cdk8 of the Mediator Complex' - Pavel Kovarik, Max F Perutz Laboratories University of Vienna


• 'Targeting STAT5 in CML: Mechanism-of-action of JAK2 Tyrosine Kinase Inhíbitors Unmask a Direct BCR/ABL-STAT5 Axis' - Veronika Sexl, Insitute of Pharmacology and Toxicology University of Veterinary Medicine Vienna


• 'STAT1 Isoform Functions: Insights from Knockin Mice - Birgit Strobl, Institute of Animal Breeding and Genetics University of Veterinary Medicine Vienna

Meeting Summary

The 2010 FEBS Special Meeting on Jak-Stat Signalling: from Basics to Disease took place in Vienna at the University of Veterinary Medicine from 10 to 13 February 2010. It was sponsored by FEBS and substantially supported by the Austrian Science Fund FWF and Boehringer Ingelheim. Previous European meetings on the topic had taken place in Aachen, Germany under the leadership of Peter Heinrich, who had founded the first European research programme to concentrate on Jak-Stat. The Vienna meeting was the first one to be held after Heinrich’s retirement and it was hoped that it would pave the way for a long series of successful meetings. More than two hundred fifty delegates arrived on time at the festival room of Vetmeduni Vienna, which hosted the meeting. The speakers represented a manifold of disciplines from all over the world who presented their latest results. This was a broad basis that opened a vivid discussion together with an international audience and last but not least with the “founding fathers” of Jak-Stat research, Jim Darnell, The Rockefeller University, New York, USA and George Stark, Cleveland Clinical, Cleveland, USA. In addition to the two keynote lectures by Darnell and Stark the scientific programme was structured in eight sessions, i.e. Jak/Stat Structure and Regulation; Negative Regulation of Jak/Stat Signalling; Transcriptional Regulation and Epigenetics; Jaks, Stats and Cancer; Jaks and Stats and Immune Response to Tumors; Jaks and Stats in Infection, Inflammation and Autoimmunity; Jaks and Stats in Development and Cell Differentiation; and Jaks and Stats in the Regulation of Immunity and Immunopathology.

Speakers List

• Christine A. Biron (University of North Carolina, Providence, USA)
• Rod Bremner (Toronto Western Hospital, Toronto, Canada)
• Iain L. Campbell (University of Sydney, Sydney, Australia)
• Ana Costa-Pereira (Imperial College London, London, UK)
• James E. Darnell (The Rockefeller University, New York, USA)
• Mark Dawson (University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK)
• Isabelle Dusanter-Fourt (Institut Cochin INSERM, Paris, France)
• Gerardo Ferbeyre (University de Montréal, Montreal, Canada)
• Shreevrat Goenka (Indiana University School of Medicine, Indianapolis, USA)
• Anthony R. Green (University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK)
• Serge Haan (University of Luxembourg, Luxembourg, Luxembourg)
• Thorsten Heinzel (Friedrich-Schiller Univerisity Jena, Jena, Germany)
• Douglas J. Hilton (The Walter And Eliza Hall Institute of Medical Research, Victoria, Australia)
• Friedemann Horn (University Hospital Leipzig, Leipzig, Germany)
• Curt M. Horvath (Northwestern University, Evanston, Chicago, USA)
• Giorgio Inghirami (University of Turin, Turin, Italy)
• Shai Izraeli (Sheba Medical Center, Tel Aviv, Israel)
• Jim Johnston (Queen's University Belfast, Belfast, UK)
• Ulrich Kalinke (Twincore-Centre for Experimental and Clinical Infection Research, Hannover, Germany)
• Mark H. Kaplan (Indiana University School of Medicine, Indianapolis, USA)
• Antonis E. Koromilas (Lady Davis Institute-Jewish General Hospital, Montreal, Canada)
• Mario Köster (Helmholtz Centre for Infection Research, Braunschweig, Germany)
• David E. Levy (NYU Medical Center, New York, USA)
• Richard Moriggl (Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria)
• Gerhard Müller-Newen (Universitätsklinikum RWTH Aachen, Aachen, Germany)
• Sandra Pellegrini (Institut Pasteur, Paris, France)
• Valeria Poli (University of Turin, Turin, Italy)
• Gertraud W Robinson (NIDDK, National Institutes of Health, Bethesda, USA)
• Fred Schaper (University Hospital Aachen, AÖR, Aachen, Germany)
• Christian W. Schindler (Columbia University, New York, USA)
• Katherine J. Seidl (Pfizer, Cambridge, USA)
• Veronika Sexl (Medical University of Vienna, Vienna, Austria)
• Vijay Shanker (University Hospital Basel, Basel, Switzerland)
• Olli Silvennoinen (University of Tampere, Tampere, Finland)
• George R. Stark (Lerner Research Institute, Cleveland, USA)
• Uwe Vinkemeier (Nottingham University Medical School, Nottingham, UK)
• Kay-Uwe Wagner (University of Nebraska Medical Center, Omaha, USA)
• Stephanie S. Watowich (UT M. D. Anderson Cancer Center, Houston, USA)
• Christine J. Watson (University of Cambridge, Cambridge, UK)